These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 19401550

  • 1. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.
    Slamon DJ, Press MF.
    J Natl Cancer Inst; 2009 May 06; 101(9):615-8. PubMed ID: 19401550
    [No Abstract] [Full Text] [Related]

  • 2. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
    O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI.
    J Natl Cancer Inst; 2009 May 06; 101(9):644-50. PubMed ID: 19401546
    [Abstract] [Full Text] [Related]

  • 3. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
    Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M, HER2/TOP2A Meta-analysis Study Group.
    Lancet Oncol; 2011 Nov 06; 12(12):1134-42. PubMed ID: 21917518
    [Abstract] [Full Text] [Related]

  • 4. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
    Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ.
    J Clin Oncol; 2011 Mar 01; 29(7):859-67. PubMed ID: 21189395
    [Abstract] [Full Text] [Related]

  • 5. Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer.
    Buzdar AU.
    J Clin Oncol; 2006 Jun 01; 24(16):2409-11. PubMed ID: 16682721
    [No Abstract] [Full Text] [Related]

  • 6. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    Scandinavian Breast Group Trial 9401Laboratory of Cancer Biology, Institute of Medical Technology, and Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.
    J Clin Oncol; 2006 Jun 01; 24(16):2428-36. PubMed ID: 16682728
    [Abstract] [Full Text] [Related]

  • 7. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
    Wang J, Xu B, Yuan P, Zhang P, Li Q, Ma F, Fan Y.
    Breast Cancer Res Treat; 2012 Sep 01; 135(2):531-7. PubMed ID: 22864769
    [Abstract] [Full Text] [Related]

  • 8. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
    Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS.
    Breast Cancer Res Treat; 2007 Dec 01; 106(2):181-9. PubMed ID: 17260090
    [Abstract] [Full Text] [Related]

  • 9. Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
    Oakman C, Moretti E, Sotiriou C, Viale G, Di Leo A.
    J Natl Cancer Inst; 2009 Dec 16; 101(24):1735-6; author reply 1736-7. PubMed ID: 19893008
    [No Abstract] [Full Text] [Related]

  • 10. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
    Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, de Vries EG, Rodenhuis S, van de Vijver MJ.
    Br J Cancer; 2006 Nov 20; 95(10):1334-41. PubMed ID: 17088909
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
    Fountzilas G, Dafni U, Bobos M, Kotoula V, Batistatou A, Xanthakis I, Papadimitriou C, Kostopoulos I, Koletsa T, Tsolaki E, Televantou D, Timotheadou E, Koutras A, Klouvas G, Samantas E, Pisanidis N, Karanikiotis C, Sfakianaki I, Pavlidis N, Gogas H, Linardou H, Kalogeras KT, Pectasides D, Dimopoulos MA.
    BMC Cancer; 2013 Mar 28; 13():163. PubMed ID: 23537287
    [Abstract] [Full Text] [Related]

  • 12. Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer.
    Almeida D, Gerhard R, Leitão D, Davilla C, Damasceno M, Schmitt F.
    Pathol Res Pract; 2014 Oct 28; 210(10):675-9. PubMed ID: 25042383
    [Abstract] [Full Text] [Related]

  • 13. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.
    Schindlbeck C, Mayr D, Olivier C, Rack B, Engelstaedter V, Jueckstock J, Jenderek C, Andergassen U, Jeschke U, Friese K.
    J Cancer Res Clin Oncol; 2010 Jul 28; 136(7):1029-37. PubMed ID: 20052594
    [Abstract] [Full Text] [Related]

  • 14. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.
    Oncology; 2011 Jul 28; 80(3-4):269-77. PubMed ID: 21734419
    [Abstract] [Full Text] [Related]

  • 15. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
    Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, Poole CJ.
    Lancet Oncol; 2010 Mar 28; 11(3):266-74. PubMed ID: 20079691
    [Abstract] [Full Text] [Related]

  • 16. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
    Villman K, Sjöström J, Heikkilä R, Hultborn R, Malmström P, Bengtsson NO, Söderberg M, Saksela E, Blomqvist C.
    Acta Oncol; 2006 Mar 28; 45(5):590-6. PubMed ID: 16864174
    [Abstract] [Full Text] [Related]

  • 17. Does topoisomerase II-alpha gene amplification provide useful information for treatment selection in patients with breast carcinoma?
    Simon R.
    J Clin Oncol; 2011 Jul 20; 29(21):2941; author reply 2941-4. PubMed ID: 21670460
    [No Abstract] [Full Text] [Related]

  • 18. Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?
    Pritchard KI.
    J Clin Oncol; 2009 Aug 20; 27(24):3875-6. PubMed ID: 19620479
    [No Abstract] [Full Text] [Related]

  • 19. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Tibau A, López-Vilaró L, Pérez-Olabarria M, Vázquez T, Pons C, Gich I, Alonso C, Ojeda B, Ramón y Cajal T, Lerma E, Barnadas A, Escuin D.
    Neoplasia; 2014 Oct 20; 16(10):861-7. PubMed ID: 25379022
    [Abstract] [Full Text] [Related]

  • 20. Anthracyclines, HER2, and TOP2A: the verdict.
    Bonnefoi HR.
    Lancet Oncol; 2011 Nov 20; 12(12):1084-5. PubMed ID: 21917520
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.